Study Background

This Phase 2 trial evaluates the combination of belinostat, etoposide, and cisplatin in patients with high‑grade neuroendocrine carcinoma (HGNEC), with dose adjustments based on the patient’s UGT1A1 genetic variant, which influences drug metabolism rates. The UGT1A1 genotype is a key genetic determinant of enzyme activity responsible for drug metabolism; variants can lead to rapid fluctuations in drug concentrations. Consequently, genotype‑guided dose personalization may enhance therapeutic efficacy while minimizing adverse events.

Clinical Design

The study administers treatment in 21‑day cycles for up to six cycles, with intravenous infusion of the three agents during the first four days of each cycle. Primary endpoints include plasma drug concentrations, toxicity profile, and tumor response. Patients are stratified into two arms, receiving either escalated or reduced doses according to their UGT1A1 genotype.

Current Treatment Landscape and Differentiation

The current standard of care for HGNEC combines belinostat with chemotherapy, applying a uniform dose across all patients. Patients harboring UGT1A1 variants may experience slower drug metabolism, increasing toxicity risk. This trial personalizes dosing based on genetic differences, aiming to improve efficacy and reduce adverse events relative to conventional therapy.

Expected Impact and Significance

If successful, the trial will generate genotype‑guided dosing guidelines that could be extended to other anticancer agents. This would set a precedent for genotype‑based dose optimization in precision medicine, potentially lowering treatment costs and improving patient quality of life over the long term.